

~~Page 49, line 11: before "," add -- (complement of nucleotides 4518-4537 of~~

~~SEQ ID NO: 8) -- SEQ ID NO: 27~~

Line 12: before "." add (nucleotides 4130-4146 of SEQ ID NO: 8) --

Page 50, line 3: before "," add (nucleotides 4151-4168 of SEQ ID NO: 8) --

Line 5: before "." add -- (complement of nucleotides 4299-4317 of SEQ ID NO: 8) --

Page 51, line 8: following "Tyr" add -- (SEQ ID NO: 26) --

Please replace the current paper copy of sequence information with the attached paper copy, and replace the current CFR with the attached diskette.

REMARKS

The examiner is called upon to explain why the claims were not examined and acted upon.

The examiner is also called upon to explain why the action was misaddressed, notwithstanding the filing of a change of address form with applicants' response of February 1.

Page 39 is corrected and, to simplify matters, the sequence listing at page 39 is deleted.

Pages 49, 50 & 51 are amended in an appropriate fashion. Note that several of these sequences are complements of sequences in the listing. The undersigned hereby declares that, to the best of his knowledge, the accompanying sequence information (paper and CRF), are identical to each other and to the information presented in the application as originally filed. No new matter is believed to be presented herein.

Applicants had 5 hours of interviews with BPS Schwartz, SPE Chan, and Examiner Cunningham on December 21 and 22. They were promised an action on the merits. They are entitled to it.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 
Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000